GLP-1 Therapy After Bariatric Surgery in Chinese Patients With Obesity
ConditionObesity
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-60
SponsorChina-Japan Friendship Hospital
About this trial
Obese patients exhibit considerable heterogeneity and complex comorbidities, making long-term effective management challenging with monotherapy. While bariatric surgery remains the most effective weight-loss intervention, postoperative weight regain and metabolic deterioration remain significant concerns. glucagon-like peptide-1 receptor agonists (GLP-1RA) offer distinct advantages for weight loss and metabolic control, and their combination with surgery may produce synergistic effects. This study investigates the efficacy and safety of bariatric surgery combined with adjuvant GLP-1 receptor agonist therapy for Chinese patients with obesity.
Eligibility criteria
Qualifiers
Patients undergoing initial laparoscopic sleeve gastrectomy (LSG).
obesity:BMI ≥30 kg/m².
Metabolic comorbidities: Diagnosis of metabolic syndrome or type 2 diabetes mellitus (T2DM) meeting standard criteria.
Age range: 18-60 years (inclusive).
Disqualifiers
Recent GLP-1RA use: Treatment with GLP-1 receptor agonists within 6 months preoperatively.
Prior bariatric surgery: History of any metabolic/bariatric surgical procedure.
Postoperative complications: Requiring reoperation for severe complications (e.g., hemorrhage, anastomotic leak).
Non-indicated candidates: Patients not meeting standard bariatric surgery indications.
Trial design
Treatments tested in this trial
- LSG-Semaglutide group
- LSG-Mazdutide group
- LSG-Tirzepatide group
- LSG group
Treatment groups
200 Participants
are divided into 4 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov